Reunion Neuroscience Archives

StaffJune 29, 2023

The Daily Hit is a recap of the top financial news stories for June 29, 2023. On the Site Canopy Growth Sells Property, Assets in Bid to Raise Cash Beleaguered Canada-based Canopy Growth Corp. (TSX: WEED) (Nasdaq: CGC) announced Thursday that it sold one of its California facilities in the town of Modesto. The sale […]

John SchroyerJune 29, 2023

Reunion Neuroscience is expected to go private later this year.

Adam JacksonJune 1, 2023

The companies expect a third-quarter close.

StaffMarch 14, 2023

The Daily Hit is a recap of the top financial news stories for March 14, 2023. On the Site Ascend Increases Revenue in Q4, but Still Not Profitable New York-based Ascend Wellness Holdings Inc. (CSE: AAWH.U) (OTCQX: AAWH) got leaner and meaner while also expanding its footprint significantly in 2022, but that wasn’t enough to […]

Adam JacksonMarch 14, 2023

Psychedelic clinical research firm Reunion Neuroscience Inc. (NASDAQ: REUN) is taking Mindset Pharma Inc. (OTCQB: MSSTF) to federal court over claims that the company copied its main psychedelic formula and presented it as its own invention while applying for a patent. Reunion filed a lawsuit against Mindset in the U.S. District Court for the District of […]

Debra BorchardtFebruary 14, 2023

Reunion Neuroscience Inc. (NASDAQ: REUN) reported financial results for the third quarter ending December 31, 2022 with no revenue for the biotech company. Reunion did report a net loss from continuing operations of $12.5 million or $1.07 per share for the three versus a loss of $5.9 million or $0.51 per share for the same […]

Debra BorchardtJanuary 9, 2023

Reunion will present findings to the FDA.

Dave HodesJanuary 6, 2023

Business analysts take to their crystal balls to provide an industry outlook.

Dave HodesDecember 21, 2022

Also a peek at their plans for the year ahead.

Debra BorchardtAugust 16, 2022

Field Trip Health has changed its name to Reunion Neuroscience Inc. (TSX: FTRP)(Nasdaq: FTRP) and reported its fiscal first quarter 2023 results for the period ending June 30, 2022. Reunion reported expenses of $5 million and a net loss of $13 million. The increase in net loss from the prior year primarily reflected the company’s […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: Reunion Neuroscience

The Daily Hit: June 29, 2023

Reunion Neuroscience Posts $48 Million Loss Ahead of Acquisition

MPM BioImpact to Acquire Reunion Neuroscience for $13.1 Million in All-Cash Deal

Daily Hit: March 14, 2023

Psychedelic Patent Battle Heats Up Between Reunion Neuroscience And Mindset Pharma

Reunion Neuroscience Reports Earnings, Update on Postpartum Drug Study

Postpartum Depression Psychedelic Treatment Studied In Reunion’s Phase 1 Trial

An Objective Look at the Psychedelics Industry for 2023

How 5 Psychedelics Companies Fared in 2022

Field Trip Health is Now Reunion Neuroscience

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox

Get the latest cannabis news delivered right to your inbox